Research topics
Drug discovery articles covering therapeutic targets, early drug development, pathway research, and emerging treatment ideas in IBD.
47 articles
Understanding how different forms of programmed cell death in the gut lining contribute to barrier loss and inflammation could point to new therapeutic targets for IBD. The review also flags natural products and...
These results highlight a new cellular mechanism (macrophage-driven ECM changes) that may protect enteric neurons during intestinal inflammation — a process linked to symptoms and complications in IBD.
This article reports that Amgen is ending a Crohn’s disease target-discovery collaboration with TScan, which could slow or change an industry pathway for immune-targeted therapies discovered through that partnership....
Reliable, high-throughput lab methods are a prerequisite for therapeutic drug monitoring (TDM). For people with IBD on JAK inhibitors, validated assays can enable exposure measurement needed for future precision dosing...
The review connects animal-model discoveries (IL-23/IL-17 and TNF pathways, gut–joint interactions) to therapies and research priorities relevant to people with SpA and IBD-associated arthritis.
This affects Crohn’s disease research funding and future drug-development pathways: a major pharmaceutical partner ended a collaboration that had aimed to discover T‑cell targets for Crohn’s disease, which could slow or...
The study introduces a novel preclinical therapeutic approach that selectively degrades HDAC6 and reduced inflammation in a mouse model of colitis, suggesting a potential new drug-discovery avenue relevant to ulcerative...
The study suggests TIMP1 may help drive ferroptosis, inflammation, and epithelial barrier dysfunction in ulcerative colitis; targeting TIMP1 could eventually inform new therapies or biomarkers if confirmed in further...
This review highlights a potential new class of IBD drugs (RIPK1 inhibitors) that target inflammatory and cell-death pathways implicated in epithelial injury. For people with IBD, it signals an area of active research...
Chronic visceral pain is common in people with IBD and IBS and current treatments often do not address nerve pathways that drive pain. Research aiming to target pain-signalling could eventually lead to more effective,...
Intestinal fibrosis causes strictures that often need surgery and has few effective medical treatments; linking the microbiome to fibrogenesis suggests new prevention or treatment strategies that could reduce surgery...
Researchers and clinicians are exploring how fucose metabolism affects gut barrier function, immunity, and microbiota — processes central to IBD and colorectal cancer. If validated, fucosylation biomarkers or treatments...
This review outlines BEVs as a microbiome-derived, engineered nanotherapy concept that could influence gut barrier repair and immune regulation—areas directly relevant to managing IBD activity and treatment resistance.
IOIBD’s consensus frameworks and educational programs shape how IBD is studied and treated worldwide — affecting trial design, treatment goals, patient-reported outcome measures, and clinical guidance that patients and...
The microbiome is increasingly viewed as an influence on IBD development and persistence, and microbiome-directed therapies (like FMT and engineered bacteria) are an active area of research that could one day add to...
This review describes a novel, targeted microbiome approach (phage therapy) aimed at bacteria linked to Crohn’s disease. If effective and proven safe in trials, phage therapy could offer a more precise way to reduce...
Researchers are developing a novel drug-discovery approach to degrade GATA3, a protein that drives Th2 inflammation in ulcerative colitis. New therapies that more directly target immune drivers could eventually help...
This preclinical study suggests cigarette smoke alters gut microbes and metabolites in ways that can either protect or worsen colitis depending on the model; it identifies 4-HBA as a metabolite that reduced inflammation...
If successful, orally available small-molecule α4β7 inhibitors could offer a non-injectable alternative to current antibody therapy (vedolizumab) that targets the same gut-homing integrin—potentially widening treatment...
TRPV channels are proposed as integrative mediators of inflammation, angiogenesis, and oxidative stress in IBD, suggesting new mechanistic targets that could eventually yield novel therapies for Crohn's disease and...
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
Identifies a redox-sensitive NOX1–ROS–IκBζ pathway that may sustain intestinal inflammation in IBD and points to a new molecular target for future therapies.
Researchers are exploring targeted nanodelivery of miR-497 to reduce oxidative stress and shift immune cells toward tissue-repairing states — a novel preclinical strategy that could eventually lead to new treatments for...
A validated human peristaltic intestinal organoid model could make preclinical testing more predictive for drugs affecting gut motility and reduce reliance on animal models.
Identifies a microbiome-derived protein that inhibits a protease linked to epithelial damage in IBD and shows protective effects in lab and mouse models, pointing to a new therapeutic strategy focused on barrier...
The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...
The study links a gut microbe (F. nucleatum) and its metabolite succinic acid to inflammatory activation of intestinal macrophages—an immune mechanism that can worsen colitis. Understanding this pathway could point...
The study uses single-cell RNA sequencing to pinpoint genes and regulatory networks that might help explain IBD biology and suggest new biomarkers or repurposed drugs. That information could guide future research toward...
New or improved fluorescent probes could enable more sensitive, noninvasive imaging of biochemical changes in the gut, which may aid research, earlier diagnosis, or monitoring of IBD and colorectal cancer.
ER stress in intestinal epithelial cells is proposed as a key molecular mechanism in UC development; targeting ER pathways (notably IRE1β) could eventually lead to new treatments that strengthen the gut barrier and...
If true, a common gut microbe (Fusobacterium nucleatum) and its metabolite succinic acid could worsen intestinal inflammation by changing macrophage behavior, suggesting new targets to reduce flares or mucosal injury in...
JAK1 inhibitors are an established therapeutic pathway in IBD; new, more selective small molecules could expand future treatment options. This study reports a novel compound with strong preclinical activity against...
The study identifies a previously unrecognized protein (TNFAIP1) that appears to promote inflammation in ulcerative colitis and proposes a compound (Salidroside) that directly binds and inhibits it in lab and mouse...
This review spotlights non-bacterial members of the gut microbiota (viruses and fungi) that may contribute to IBD by altering barrier function, immune responses, and interactions with bacteria. For people with IBD, these...
People with long-standing ulcerative colitis face an increased risk of colorectal cancer; this study highlights PPARGC1A as a gene that may be downregulated early in that progression, which could eventually help identify...
This project studies a novel enzyme target (GCPII) that is reportedly upregulated in IBD and may change glutamate signaling and barrier function; understanding it could point to new treatment strategies for people whose...
Intestinal fibrosis and strictures remain a major cause of surgery and obstruction in Crohn’s disease, and current anti-inflammatory drugs don’t reliably prevent fibrosis. If microbial choline degradation promotes...
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
This study describes a new oral immunoproteasome inhibitor (ent-F10) with preclinical activity in animal models of ulcerative colitis and rheumatoid arthritis, highlighting a potential new drug-development direction that...
The paper proposes a specific molecular link between elevated glycocholic acid (a bile acid altered in IBD) and impaired intestinal stem cell renewal via the TRIB3–ID1 pathway, which could help explain poor mucosal...
The study identifies a specific protein interaction that may underlie persistent inflammation; for people with Crohn’s and other inflammatory conditions this points to a potential new, more targeted treatment approach in...
The study maps cell types and signals linked to submucosal scarring in Crohn's disease, a complication without drug treatments that often requires surgery. Understanding these mechanisms could point to future therapeutic...
People with Crohn’s disease who have an ileostomy have limited noninvasive ways to monitor small-bowel inflammation. This study suggests measuring fecal calprotectin from ileostomy output could help detect postoperative...
Researchers are exploring whether gut microbes differ in patients who develop fibrous strictures — a common, surgery-prone complication of Crohn’s disease — because that could help predict risk or point to new prevention...
New FDA approval adds another IL‑23p19 biologic option for moderate‑to‑severe Crohn’s disease and highlights two‑year efficacy data, which may affect treatment choices and future pediatric availability.
This research uses patient-derived “mini-guts” to uncover epigenetic changes that may help explain differences between people with Crohn’s disease and could point to new biological pathways for future therapies.
